

## INDEX

---

*Note: Entries followed by  
“f” indicate figures; “t” tables.*

- 1800/1500 Rule, 105t
- A1C (glycosylated hemoglobin) testing, 57-58, 58t, 69-75, 71, 135-139, 136t
- Absorption factors (insulin), 80-86, 81t
- Accu-Check meters (Advantage and Compact), 146t
- ACE (angiotensin-converting enzyme) inhibitors, 228-232, 244-246
- Acetaminophen, 235
- Acute complications, 195-218. *See also* Complications.
  - differential diagnoses and, 201-213, 203t, 208t, 211t-212t
  - DKA, 195-197, 197t, 203t
  - hypoglycemia, 197t, 214-218
  - overviews of, 195, 197t
  - reference resources for, 218
- ADA (American Diabetes Association), 23-33, 139-153, 220
  - diabetes classification of, 23-33. *See also* Classification.
  - glycemic control recommendations of, 220
  - SMBG goals of, 139-153
- Addison’s disease, 43
- Alcohol recommendations, 65t
- ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial), 232
- American Diabetes Association. *See* ADA (American Diabetes Association).
- Amitriptyline, 235
- Amoxicillin trihydrate, 238-239
- Amylin, 20-21, 174f
- Anemia (pernicious), 43
- Angiotensin-converting enzyme inhibitors. *See* ACE (angiotensin-converting enzyme) inhibitors.
- Animas Corporation, 122
- Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. *See* ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
- Antiseizure medications, 234

Apidra, 72t  
Ascensia meters (DEX and Elite XL), 146t  
Aspart. *See* Insulin aspart.  
Aspirin, 234, 236f  
Asymptomatic patients (diagnoses), 51-52, 53t  
  for type 1 diabetes, 51-52, 53t  
  for type 2 diabetes, 52, 53t  
Atkins Diet, 62  
Autoimmune disease associations, 43-44  
Autonomic neuropathies, 233

Basal insulin therapy, 88-89  
Basal rate verification, 125  
Basic topics. *See* Overviews.  
BD meters (Latitude and Logic), 146t-147t  
Beta-blockers, 246  
Blood glucose meters, 146t-148t  
  listing of, 146t-148t  
  memory meters, 156-157  
Blood-letting devices, 145  
Bolus rate determination, 125-127

Calcium channel blockers, 246-247  
Capsaicin (topical), 234  
Carbamazepine, 234  
Carbohydrates, 17-18, 18f, 64t  
  metabolism of, 17-18, 18f  
  recommendations for, 64t  
Cardiovascular reflexes (impaired), 239  
Carvedilol, 247  
Case presentations, 163-165  
Catecholamines, 21  
Celiac disease, 43-44  
CHD (coronary heart disease), 243  
Cialis, 241  
Ciprofloxain HCl, 238-239  
Cisapride, 237-238  
Classification, 23-33  
  ADA revisions to, 23-33  
  diagnoses and, 45-53. *See also* Diagnoses.  
  GDM, 23, 32  
  historical perspectives of, 23-24

Classification (*continued*)  
IDDM, 23  
  juvenile onset diabetes, 23  
LADA, 23, 24t-25t, 29-31  
lipodystrophic diabetes, 24t-25t, 31-32  
MODY, 23, 24t-25t, 29  
  glucokinase MODY (MODY-2), 24t-25t, 29  
  transcription factor MODY, 24t-25t, 29  
NIDDM, 23  
  overviews of, 23, 24t-25t  
  pancreatic diabetes, 24t-25t, 27-28  
  prediabetes (IGT and IFG), 26  
  reference resources for, 33  
  type 1 diabetes, 23, 24t-25t, 26-27  
  type 1.5 diabetes, 23, 24t-25t, 29-31  
  type 1A diabetes, 23, 24t-25t  
  type 1B diabetes (idiopathic diabetes), 23, 24t-25t, 27  
  type 2 diabetes, 23, 24t-25t, 28-29  
  type 3 diabetes (double diabetes), 24t-25t, 31-32  
Clinical efficacy (pramlintide therapy), 176-188, 178f-182f, 184f-188f  
Clinical trials and research studies, 42-43, 115-116, 141-142, 220, 226, 231-232, 245-246  
ALLHAT, 232  
DCCT, 69, 115-116, 141-142, 220, 231  
DPT-1, 42  
Early Treatment Diabetic Retinopathy Study, 226  
ENDIT, 42-43  
HOPE trial, 245-246  
UKPDS, 141-142, 220, 231  
Combination insulin analogues, 73t  
Complications, 195-256  
  acute, 195-218  
    differential diagnoses and, 201-213, 203t, 208t, 211t-212t  
    DKA, 127-128, 195-213, 197t-198t, 203t, 208t, 211t-212t  
    hypoglycemia, 214-218  
    overviews of, 195  
    reference resources for, 218  
  long-term, 219-256  
    diabetic foot disorders, 251-252, 253t  
    macrovascular, 243-251, 249t-250t  
    microvascular, 221-243, 222t, 224f-225f, 229f, 230t, 236f

- Complications, long-term (*continued*)  
 overviews of, 219-220  
 reference resources for, 252, 254-256
- Congenital rubella, 37, 40
- Continuous glucose monitoring, 145, 149
- Continuous subcutaneous insulin therapy. *See* CSII (continuous subcutaneous insulin therapy).
- Coronary heart disease. *See* CHD (coronary heart disease).
- Cortisol, 21
- Counterirritants, 234
- Coxsackievirus B4, 40
- Criteria (diagnostic), 45-50, 46t, 48t, 51t, 63, 65-67. *See also* Diagnoses.  
 descriptions of, 45-47, 46t, 48t  
 FPG concentrations, 45-46, 45t, 48t  
 GCTs, 50, 51t  
 OGGTs, 45-46, 45t, 48t  
 random plasma glucose testing, 45-46, 45t
- CSII (continuous subcutaneous insulin therapy), 115-134  
 basal rate verification and, 125  
 benefits of, 116-118, 116f-117f  
 everyday management for, 130-131  
 hyperglycemia (unexplained) and, 127-128  
 hypoglycemia and, 120f, 128-129  
 idealized insulin effects of, 117f  
 initiation of, 122-125, 123t-124f  
 insulin pumps and subcutaneous catheter infusion sets, 121f  
 ketoacidosis (unexplained), 127-128  
 mechanisms of, 118-122, 119f-121f  
 overviews of, 115-116  
 patient selection and education for, 131-133, 132t  
 prandial (bolus) rate determination and, 125-127  
 skin infection and, 129-130  
 therapeutic and safety features of, 123f
- DANA Diabecare USA, 122
- Data downloads, 157-162  
 interpretation of, 159-162  
 office setting logistics of, 157-158
- Data recording (SMBG), 149-159, 152t-153t
- Dawn phenomenon, 21, 90
- DCCBs (dihydropyridine calcium channel blockers), 246-247
- DCCT (Diabetes Control and Complications Trial), 69, 115-116, 141-142, 220, 231
- Deltec, Inc., 122
- Detemir. *See* Insulin detemir.
- Development stages, 36f
- Diabetes Control and Complications Trial. *See* DCCT (Diabetes Control and Complications Trial).
- Diabetes Prevention Trial-Type 1 Diabetes. *See* DPT-1 (Diabetes Prevention Trial-Type 1 Diabetes).
- Diabetes (type 1) management topics. *See also under individual topics.*  
 classification, 23-33  
 complications, 195-256  
 acute, 195-218  
 long-term, 219-256  
 diagnoses, 45-53  
 epidemiology, 13-16  
 fuel metabolism mechanisms, 17-22  
 glycemic goals, 55-60  
 glycemic status monitoring, 135-154  
 insulin therapy, 69-134  
 CSII, 115-134  
 multiple-component insulin therapy, 69-114  
 nonpharmacologic management, 61-67  
 overviews. *See* Overviews.  
 pathogenesis, 35-44  
 pattern management with blood glucose data technology, 155-167  
 pramlintide therapy, 169  
 reference resources. *See* Reference resources.
- Diabetic diarrhea, 238-239
- Diabetic foot disorders, 251-252, 253t
- Diabetic ketoacidosis. *See* DKA (diabetic ketoacidosis).
- Diabetic nephropathy, 226-232, 229f, 230t
- Diabetic neuropathy, 223-242, 233t, 236f
- Diabetic retinopathy, 221-226, 224f-225f
- Diagnoses, 45-53  
 of asymptomatic individuals, 51-52, 53t  
 for type 1 diabetes, 51-52, 53t  
 for type 2 diabetes, 52, 53t

Diagnoses (*continued*)

classification and, 23-33. *See also* Classification.

diagnostic criteria, 45-50, 46t, 48t, 51t

descriptions of, 45-47, 46t, 48t

FPG concentrations, 45-46, 45t, 48t

GCTs, 50, 51t

OGGTs, 45-46, 45t, 48t

random plasma glucose testing, 45-46, 45t

GDM testing, 49-51, 51t

overviews of, 45

reference resources for, 52

type 1 vs type 2 diabetes, 47-48

Diarrhea (diabetic), 238-239

Dietary considerations, 61-62, 64t-65t. *See also* MNT  
(medical nutrition therapy).

alcohol recommendations, 65t

Atkins Diet and, 62

carbohydrate recommendations, 64t

descriptions of, 61

fat recommendations, 64t-65t

goals of, 61

micronutrient recommendations, 65t

nutritional recommendations, 62, 64t-65t

personalized nutrition plans, 62

protein recommendations, 64t

sodium recommendations, 65t

team approaches to, 61

Differential diagnoses (acute complications), 201-213,  
203t, 208t, 211t-212t. *See also* Acute complications.

Dihydropyridine calcium channel blockers. *See* DCCBs  
(dihydropyridine calcium channel blockers).

Diuretics, 247

DKA (diabetic ketoacidosis), 127-128, 195-213,  
197t-198t, 203t, 208t, 211t-212t

Domperidone, 238

Dose determinations (insulin therapy), 98-102, 99f, 100t

Double diabetes. *See* Type 3 diabetes (double diabetes).

Doxycycline hyclate, 238-239

DPT-1 (Diabetes Prevention Trial-Type 1 Diabetes), 42

Dyslipidemia, 247-251, 249t-250t

Early Treatment Diabetic Retinopathy Study, 226

Efficacy (pramlintide therapy), 176-188, 178f-182f,  
184f-188f

Empiric risks, 40t. *See also* Risk identification.

ENDIT (European Nicotinamide Diabetes Intervention  
Trial), 42-43

Environmental factors, 37, 40. *See also* Pathogenesis.

Epidemiology, 13-16

incidence data, 13-15, 14f

overviews of, 13-14

prevalence data, 13-15

reference resources for, 15-16

regional variation data, 14f, 15

risk identification data, 15

Erectile dysfunction, 240-243

Erythromycin, 237-238

European Nicotinamide Diabetes Intervention Trial.  
*See* ENDIT (European Nicotinamide Diabetes  
Intervention Trial).

Exercise, 63, 65-67

descriptions of, 63, 65

graded exercise tests, 65-66

precautionary measures for, 66-67

Extended insulin zinc suspension, 71, 72t. *See also*  
Ultralente.

Fasting plasma glucose concentrations. *See* FPG (fasting  
plasma glucose) concentrations.

Fat, 19, 64t-65t

metabolism of, 19

recommendations for, 64t-65t

FDA (Food and Drug Administration), 71, 171, 237-238

Foot disorders (diabetic), 251-252, 253t

FPG (fasting plasma glucose) concentrations, 45-46, 45t, 48t  
Freestyle, 147t

Fuel metabolism mechanisms, 17-22

glucoregulatory hormones, 19-21

amylin, 20-21

catecholamines, 21

cortisol, 21

descriptions of, 19

glucagon, 20

- Fuel metabolism mechanisms, gluco regulatory hormones (*continued*)  
 growth hormone, 21  
 insulin, 19-20  
 of normal metabolism, 17-19, 18f  
 carbohydrate metabolism, 17-18, 18f  
 descriptions of, 17  
 fat metabolism, 19  
 protein metabolism, 19  
 overviews of, 17  
 reference resources for, 22
- Fundamental topics. *See* Overviews.
- Future perspectives, 191-192
- Gabapentin, 234, 235, 236f
- Gastric emptying slowing, 173-174
- Gastroparesis, 235-238
- GCTs (glucose challenge tests), 50, 51t
- GDM (gestational diabetes mellitus), 23, 32, 49-60  
 descriptions of, 23, 32  
 diagnoses of, 49-51, 51t  
 glycemic goals for, 59-60  
 testing for, 49-51, 51t
- Glargine. *See* Insulin glargine.
- Glucagon, 20, 174f, 175-176
- Glucokinase MODY (MODY-2), 24t-25t, 29
- Gluco regulatory hormones, 19-21. *See also* Fuel metabolism mechanisms.  
 amylin, 20-21  
 catecholamines, 21  
 cortisol, 21  
 descriptions of, 19  
 glucagon, 20  
 growth hormone, 21  
 insulin, 19-20
- Glucose appearance-disappearance, 171-173, 172f
- Glucose challenge tests. *See* GCTs (glucose challenge tests).
- Glucowatch Automatic Glucose Biographer, 145, 149
- Glulisine. *See* Insulin glulisine.
- Glycemic goals, 55-60. *See also* Glycemic status monitoring.  
 A1C testing and, 57-58, 58t  
 assessment of, 57  
 intensive management benefits and, 56t  
 pregnancy and GDM, 59-60  
 recommendations for, 57, 58t  
 SMBG and, 59. *See also* SMBG (self-monitoring of blood glucose).
- Glycemic status monitoring, 135-154  
 glycemic goals and, 55-60. *See also* Glycemic goals.  
 by health care teams, 135-139, 136t  
 A1C testing, 135-139, 136t  
 SMBG reviews, 135-136, 135t. *See also* SMBG (self-monitoring of blood glucose).  
 overviews of, 135  
 by patients, 139-151, 140t, 143t, 146t-148t, 152f-153f  
 descriptions of, 139  
 ketone monitoring, 140, 150-151  
 SMBG, 139-151, 140t, 143t, 146t-148t, 152f-153f.  
*See also* SMBG (self-monitoring of blood glucose).  
 reference resources for, 151, 154
- Glycosylated hemoglobin testing. *See* A1C (glycosylated hemoglobin) testing.
- Graded exercise tests, 65-66
- Graves' disease, 43
- Growth hormone, 21
- Health Outcomes Prevention Evaluation trial. *See* HOPE (Health Outcomes Prevention Evaluation) trial.
- Hemochromatosis, 240-243
- Historical perspectives, 23-24
- HOPE (Health Outcomes Prevention Evaluation) trial, 245-246
- Humalog, 72t
- Human leukocyte antigen alleles and susceptibility, 36-37, 38t-39t. *See also* Risk identification.
- Hyperglycemia, 22, 40, 107t, 127-128
- Hyperprolactinemia, 240-243
- Hypertension, 244-247
- Hypoglycemia, 22, 107t, 120f, 128-129, 197t, 214-218
- Hypoparathyroidism, 43

- IDDM (insulin-dependent diabetes mellitus), 23
- IDE (International Diabetes Federation), 13
- Idiopathic diabetes. *See* Type 1B diabetes (idiopathic diabetes).
- IFG (impaired fasting glucose), 26
- IGT (impaired glucose tolerance), 26
- Immunologic markers, 41. *See also* Pathogenesis.
- Immunosuppression, 42
- Impaired cardiovascular reflexes, 239
- Impaired fasting glucose. *See* IFG (impaired fasting glucose).
- Impaired glucose tolerance. *See* IGT (impaired glucose tolerance).
- Impotence (diabetic), 240-243
- Incidence data, 13-15, 14f. *See also* Epidemiology.
- InDuo meters, 147t
- Inherited polyendocrine autoimmune syndrome (type I and type II), 43-44
- Injection devices, 110-111
- Insulin analogues, 84-86
- Insulin aspart, 72t, 75-77, 83-85, 90, 103, 104t-105t, 109-111
- Insulin detemir, 77, 80
- Insulin glargine, 71, 73t, 79-80, 92f
- Insulin glulisine, 72t, 75-77, 83-85, 90, 103, 104t-105t, 109-111
- Insulin lispro, 72t, 77-85, 88-90, 103, 104t-105t, 106, 109-111
- Insulin therapy, 69-134. *See also under specific insulin preparations.*
- CSII, 115-134
- basal rate verification and, 125
  - benefits of, 116-118, 116f-117f
  - everyday management for, 130-131
  - hyperglycemia (unexplained) and, 127-128
  - hypoglycemia and, 120f, 128-129
  - idealized insulin effects of, 117f
  - initiation of, 122-125, 123t-124f
  - insulin pumps and subcutaneous catheter infusion sets, 121f
  - ketoacidosis (unexplained), 127-128
  - mechanisms of, 118-122, 119f-121f
- Insulin therapy, CSII (*continued*)
- overviews of, 115-116
  - patient selection and education for, 131-133, 132t
  - prandial (bolus) rate determination and, 125-127
  - reference resources for, 134
  - risks of, 127-130
  - skin infection and, 129-130
  - therapeutic and safety features of, 123f
  - fuel metabolism mechanisms and, 19-20
  - multiple component insulin therapy, 69-114
    - A1C testing and, 69-75
    - basal insulin therapy, 88-89
    - CSSII and, 94-96
    - dose determinations, 98-102, 99f, 100t
    - dose timing, 83
    - injection devices, 110-111
    - injection sites, 82-83
    - insulin absorption factors, 80-86, 81t
    - insulin analogue roles, 84-86
    - insulin mixtures, 80
    - insulin preparation selection, 76-80, 78f-79f
    - intermediate-acting insulin, 79
    - intermediate-acting prandial insulin, 90
    - long-acting basal insulin, 90-94
    - long-acting insulin, 79-80
    - overviews of, 69
    - physical activity and, 83-84
    - physiologic vs nonphysiologic insulin replacement, 70-76, 72t-73t, 74f-76f
    - prandial insulin therapy, 87-88
    - rapid-acting insulin, 77, 90-94
    - rapid-acting prandial insulin, 90
    - reference resources for, 111, 114
    - regimen adjustments for, 102-110, 104t-105t, 107t, 110t
    - regimens for, 86-98, 89f, 91f-93f, 97f
    - short-acting insulin, 77-78
    - TDD (total daily dose), 98-102, 99f, 100t
    - twice-daily split-mixed regimens, 96-98
  - as preventive therapy, 42-43. *See also* Preventive therapy.
- Insulin-dependent diabetes mellitus. *See* IDDM (insulin-dependent diabetes mellitus).

Intermediate-acting insulin, 79

Intermediate-acting prandial insulin, 90

International Diabetes Federation. *See* IDE (International Diabetes Federation).

Introductory topics. *See* Overviews.

Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, 244

Juvenile onset diabetes, 23

Ketoacidosis. *See* DKA (diabetic ketoacidosis).

Ketone monitoring, 140, 150-151

LADA (latent autoimmune diabetes of adults), 23, 24t-25t, 29-31, 70

Lantus, 71, 73t

Latent autoimmune diabetes of adults. *See* LADA (latent autoimmune diabetes of adults).

Lente, 71, 72t, 77, 79

Leukocyte antigen alleles and susceptibility, 36-37, 38t-39t. *See also* Risk identification.

Levitra, 241

Lipodystrophic diabetes, 24t-25t, 31-32

Lispro. *See* Insulin lispro.

Local nerve blocks, 236f

Log books, 156-157

Long-acting basal insulin, 90-94

Long-acting insulin, 79-80

Long-acting insulin analogues, 73t

Long-term complications, 219-256. *See also* Complications.

- diabetic foot disorders, 251-252, 253t
- macrovascular, 243-251, 249t-250t
  - descriptions of, 243
  - dyslipidemia, 247-251, 249t-250t
  - hypertension, 244-247
- microvascular, 221-243, 222t, 224f-225f, 229f, 230t, 236f
  - descriptions of, 221
  - diabetic nephropathy, 226-232, 229f, 230t
  - diabetic neuropathy, 223-242, 233t, 236f
  - diabetic retinopathy, 221-226, 224f-225f
- overviews of, 219-220, 222f
- reference resources for, 252, 254-256

Macrovascular complications, 243-251, 249t-250t

- descriptions of, 243
- dyslipidemia, 247-251, 249t-250t
- hypertension, 244-247

Management topics (type 1 diabetes). *See also under individual topics.*

- classification, 23-33
- complications, 195-256
  - acute, 195-218
  - long-term, 219-256
- diagnoses, 45-53
- epidemiology, 13-16
- fuel metabolism mechanisms, 17-22
- glycemic goals, 55-60
- glycemic status monitoring, 135-154
- insulin therapy, 69-134
  - CSSI, 115-134
  - multiple-component insulin therapy, 69-114
- nonpharmacologic management, 61-67
- overviews. *See* Overviews.
- pathogenesis, 35-44
- pattern management with blood glucose data technology, 155-167
- pramlintide therapy, 169
- reference resources. *See* Reference resources.

Maturity-onset diabetes of youth. *See* MODY (maturity-onset diabetes of youth).

Medical nutrition therapy. *See* MNT (medical nutrition therapy).

Medtronic MiniMed, 122

Memory meters, 156-157

Metabolism mechanisms, 17-22

- glucoregulatory hormones, 19-21
  - amylin, 20-21
  - catecholamines, 21
  - cortisol, 21
  - dawn phenomenon and, 21
- descriptions of, 19
- glucagon, 20
- growth hormone, 21
- insulin, 19-20

- Metabolism mechanisms (*continued*)  
of normal metabolism, 17-19, 18f  
fat metabolism, 19  
protein metabolism, 19  
overviews of, 17  
reference resources for, 22
- Meters (blood glucose), 146t-148t, 156-157  
listing of, 146t-148t  
memory meters, 156-157
- Metoclopramide HCl, 238-239
- Metronidazole, 238-239
- Micronutrient recommendations, 65t
- Microvascular complications, 221-243, 222t, 224f-225f, 229f, 230t, 236f  
descriptions of, 221  
diabetic nephropathy, 226-232, 229f, 230t  
diabetic neuropathy, 223-242, 233t, 236f  
diabetic retinopathy, 221-226, 224f-225f
- MNT (medical nutrition therapy), 61-62, 64t-65t  
alcohol recommendations, 65t  
Atkins Diet and, 62  
carbohydrate recommendations, 64t  
descriptions of, 61  
fat recommendations, 64t-65t  
goals of, 61  
micronutrient recommendations, 65t  
nutritional recommendations, 62, 64t-65t  
personalized nutrition plans, 62  
protein recommendations, 64t  
sodium recommendations, 65t  
team approaches to, 61
- MODY (maturity-onset diabetes of youth), 23, 24t-25t, 29  
glucokinase MODY (MODY-2), 24t-25t, 29  
transcription factor MODY, 24t-25t, 29
- Mononeuropathy, 235
- Multiple-component insulin therapy, 69-114
- Myasthenia gravis, 43
- Narcotic analgesics, 234
- NDCCBs (nondihydropyridine calcium channel blockers), 246-247
- Nephropathy (diabetic), 226-232, 229f, 230t
- Nephrotoxic drugs, 227
- Neurogenic bladder, 239
- Neurontin, 234
- Neuropathy (diabetic), 223-242, 233t, 236f
- Neutral protamine Hagedorn. *See* NPH (neutral protamine Hagedorn).
- Nicotinamide intervention, 42-43
- NIDDM (non-insulin-dependent diabetes mellitus), 23.  
*See also* Type 2 diabetes.
- Nipro Diabetes Systems, 122
- Nondihydropyridine calcium channel blockers.  
*See* NDCCBs (nondihydropyridine calcium channel blockers).
- Non-insulin-dependent diabetes mellitus.  
*See* NIDDM (non-insulin-dependent diabetes mellitus); Type 2 diabetes.
- Nonpharmacologic management, 61-67  
exercise, 63, 65-67  
descriptions of, 63, 65  
graded exercise tests, 65-66  
precautionary measures for, 66-67
- MNT, 61-62, 64t-65t  
alcohol recommendations, 65t  
Atkins Diet and, 62  
carbohydrate recommendations, 64t  
descriptions of, 61  
fat recommendations, 64t-65t  
goals of, 61  
micronutrient recommendations, 65t  
nutritional recommendations for, 62, 64t-65t  
personalized nutrition plans, 62  
protein recommendations, 64t  
sodium recommendations, 65t  
team approaches to, 61  
overviews of, 61  
reference resources for, 67
- Nonphysiologic vs physiologic insulin replacement, 70-76, 72t-73t, 74f-76f
- Nonproliferative diabetic retinopathy, 223, 224f

- Normal metabolism, 17-19, 18f. *See also* Metabolism mechanisms.
- carbohydrate metabolism, 17-18, 18f
  - descriptions of, 17
  - fat metabolism, 19
  - protein metabolism, 19
- NovoLog, 72t, 128
- NPH (neutral protamine Hagedorn), 69, 71, 72t, 77, 78f-79f, 79, 80-98, 91f, 97f, 99f, 111, 120
- Nutrition therapy (medical). *See* MNT (medical nutrition therapy).
- Nutritional recommendations, 62, 64t-65t. *See also* MNT (medical nutrition therapy).
- OGGTs (oral glucose tolerance tests), 45-46, 45t, 48t
- OneTouch meters (Surestep, Ultra, and UltraSmart), 147t-148t
- Oral glucose tolerance tests. *See* OGGTs (oral glucose tolerance tests).
- Overviews. *See also under individual topics.*
- of classification, 23, 24t-25t
  - of complications, 195, 219-220
    - acute, 195
    - long-term, 219-220
  - of diagnoses, 45
  - of epidemiology, 13-14
  - of fuel metabolism mechanisms, 17
  - of glycemic status monitoring, 135
  - of insulin therapy, 69, 115-116
    - CSII, 115-116
    - multiple component insulin therapy, 69
  - of nonpharmacologic management, 61
  - of pathogenesis, 35-36, 36f
  - of pattern management with blood glucose data technology, 155-156
  - of pramlintide therapy, 169-171, 170t
- Pancreatic diabetes, 24t-25t, 27-28
- Pathogenesis, 35-44
- autoimmune disease associations, 43-44
    - Addison's disease, 43-44
    - celiac disease, 43-44
  - Pathogenesis, autoimmune disease associations (*continued*)
    - Graves' disease, 43
    - hypoparathyroidism, 43
    - hypothyroidism, 43
    - inherited polyendocrine autoimmune syndrome (type I and type II), 43-44
    - myasthenia gravis, 43
    - pernicious anemia, 43
  - development stages, 36f
  - environmental factors, 37, 40
    - congenital rubella, 37, 40
    - coxsackievirus B4, 40
    - hyperglycemia, 40
    - thyroiditis, 40
    - viral infections, 40
  - immunologic markers, 41
  - overviews of, 35-36, 36f
  - preventive therapy, 42-43
    - immunosuppression, 42
    - insulin therapy, 42-43
    - nicotinamide intervention, 42-43
    - selective T-cell deletion, 42
  - risk identification, 36-37, 38t-40t
    - empiric risks, 40t
    - human leukocyte antigen alleles and susceptibility, 36-37, 38t-39t
- Patient glycemic status monitoring, 139-151, 140t, 143t, 146t-148t, 152f-153f. *See also* Glycemic status monitoring.
- descriptions of, 139
  - ketone monitoring, 140, 150-151
  - SMBG, 139-151, 140t, 143t, 146t-148t, 152f-153f. *See also* SMBG (self-monitoring of blood glucose).
- Pattern management with blood glucose data technology, 155-167
- case presentations, 163-165
  - data downloads, 157-162
    - interpretation of, 159-162
    - office setting logistics of, 157-158
  - log books for, 156-157
  - memory meters for, 156-157
  - overviews and summaries, 155-156
  - reference resources for, 166-167

- Peripheral dopamine agonists, 238
- Pernicious anemia, 43
- Personalized nutrition plans, 62
- Pharmacological management. *See also under individual topics.*
  - insulin therapy, 69-134
    - CSII, 115-134
    - multiple-component insulin therapy, 69-114
    - pramlintide therapy, 169-194
  - Phenytoin, 234
- Physical activity and exercise, 63, 65-67
  - descriptions of, 63, 65
  - graded exercise tests, 65-66
  - precautionary measures for, 66-67
- Physiologic vs nonphysiologic insulin replacement, 70-76, 72t-73t, 74f-76f
- Polyendocrine autoimmune syndrome (type I and type II), 43-44
- Postprandial glucagon suppression, 174f, 175-176
- Pramlintide therapy, 169-194
  - action mechanisms of, 173-176, 174f-175f
    - amylin and insulin action model, 174f
    - food intake regulation, 176
    - gastric emptying slowing, 173-174
    - postprandial glucagon suppression, 174f, 175-176
    - single does vs placebo effects, 175f
  - clinical efficacy of, 176-188, 178f-182f, 184f-188f
    - hypoglycemia risks, 182-183
    - insulin therapeutic window enhancement, 183, 184f-187f, 188, 188f
    - long-term glycemic control, 177-179
    - postprandial glucose effects, 176-177, 178f-179f
    - sustained weight loss effects, 179, 180f-182f
    - tolerability, 181-182
  - dosing of, 188-189, 190t
    - descriptions of, 188-189
    - insulin unit equivalent conversions, 190t
    - for type 1 diabetes, 189
    - for type 2 diabetes, 189
  - FDA approval of, 171
  - future perspectives of, 191-192
  - glucose appearance-disappearance and, 171-173, 172f
- Pramlintide therapy (*continued*)
  - overviews of, 169-171, 170t
  - patient tips for, 190-191
    - dose timing, 190
    - dose titration, 190
    - insulin dose reduction, 191
    - insulin dose timing, 191
  - reference resources for, 192-194
- Prandial (bolus) rate determination, 125-127
- Precision meters (Q.I.D. and Xtra), 148t
- Prediabetes (IGT and IFG), 26
- Preparation selection (insulin), 76-80, 78f-79f. *See also Insulin therapy.*
- Preproliferative diabetic retinopathy, 223, 225f
- Prevalence data, 13-15. *See also Epidemiology.*
- Preventive therapy, 42-43
  - immunosuppression, 42
  - insulin therapy, 42-43
    - nicotinamide intervention, 42-43
    - selective T-cell deletion, 42
- Prokinetic agents, 237-238
- Proliferative diabetic retinopathy, 224
- Propoxyphene, 234
- Protein metabolism, 19
- Protein recommendations, 64t
- Random plasma glucose testing, 45-46, 45t
- Rapid-acting insulin, 77
- Rapid-acting prandial insulin, 90
- Reference resources. *See also under individual topics.*
  - for classification, 33
  - for complications, 218, 252, 254-256
    - acute, 218
    - long-term, 252, 254-256
  - for diagnoses, 52
  - for epidemiology, 15-16
  - for fuel metabolism mechanisms, 22
  - for glycemic status monitoring, 151, 154
  - for insulin therapy, 111, 114, 134
    - CSII, 134
    - multiple component insulin therapy, 111, 114
    - for nonpharmacologic management, 67

Reference resources (*continued*)

for pattern management with blood glucose data technology, 166-167  
for pramlintide therapy, 192-194  
Regional variation data, 14f, 15. *See also* Epidemiology.  
Research studies. *See* Clinical trials and research studies.  
Retinopathy (diabetic), 221-226, 224f-225f  
Risk identification, 15, 36-37, 38t-40t. *See also*  
Epidemiology; Pathogenesis.  
empiric risks, 40t  
human leukocyte antigen alleles and susceptibility, 36-37, 38t-39t  
statistical data, 15  
Rubella (congenital), 37, 40  
  
Selective T-cell deletion, 42  
Self-monitoring of blood glucose. *See* SMBG  
(self-monitoring of blood glucose).  
Sensorimotor peripheral neuropathies, 233  
Sexual dysfunction, 240-243  
Short-acting insulin, 77-78  
Sildenafil, 241  
Skin infection, 129-130  
SMBG (self-monitoring of blood glucose), 139-153.  
*See also* Glycemic status monitoring.  
ADA goals of, 141-143, 143t  
advances in, 144-145, 149  
blood-letting devices, 145  
continuous glucose monitoring, 145, 149  
descriptions of, 144-145  
GlucoWatch Automatic Glucose Biographer, 145, 149  
advantages vs disadvantages of, 142-143, 143t  
blood glucose meters, 146t-148t, 156-157  
Accu-Check (Advantage and Compact), 146t  
Ascensia (DEX and Elite XL), 146t  
BD (Latitude and Logic), 146t-147t  
Freestyle, 147t  
InDuo, 147t  
memory meters, 156-157  
OneTouch (Surestep, Ultra, and UltraSmart), 147t-148t  
Precision (Q.I.D. and Xtra), 148t  
data recording, 149-159, 152t-153t

SMBG (self-monitoring of blood glucose) (*continued*)

descriptions of, 139-141, 140t  
glycemic goals for, 59  
intensive management and, 140t  
recommended frequency of, 143-144  
reviews of, 135-136, 135t  
Smiths Medical MD, Inc., 122  
Sodium recommendations, 65t  
Split-mixed insulin regimens, 96-98  
Stages of development, 36f  
*Staphylococcus*, 128-129  
Statin therapy, 250  
*Streptococcus*, 128-129  
Studies. *See* Clinical trials and research studies.  
Suggested readings. *See* Reference resources.  
Sustained weight loss, 179, 180f-182f  
Symlin, 169-194. *See also* Pramlintide therapy.  
Symmetric distal neuropathies, 233-235, 233t  
  
Tadalafil, 241  
T-cell deletion, selective, 42  
TDD (total daily dose) determination, 98-102, 99f, 100t  
Tegaserod, 238  
TENS (transcutaneous electrical nerve stimulation) units, 235, 236f  
Thiazine diuretics (low-dose), 247  
Thyroiditis, 40  
Tolerability (pramlintide therapy), 181-182  
Topamax, 234  
Topical capsaicin, 234  
Topiramate, 234  
Total daily dose. *See* TDD (total daily dose) determination.  
Tramadol, 234, 236f  
Transcription factor MODY, 24t-25t, 29  
Trials. *See* Clinical trials and research studies.  
Tricyclic antidepressants, 234, 236f  
Twice-daily split-mixed insulin regimens, 96-98  
Tylenol, 235  
Type 1 diabetes management topics. *See also under individual topics.*  
classification, 23-33

Type 1 diabetes management topics (*continued*)  
complications, 195-256  
    acute, 195-218  
    long-term, 219-256  
diagnoses, 45-53  
epidemiology, 13-16  
fuel metabolism mechanisms, 17-22  
glycemic goals, 55-60  
glycemic status monitoring, 135-154  
insulin therapy, 69-134  
    CSII, 115-134  
    multiple-component insulin therapy, 69-114  
    multiple-component insulin therapy, 69-114  
nonpharmacologic management, 61-67  
overviews. *See* Overviews.  
pathogenesis, 35-44  
pattern management with blood glucose data technology,  
    155-167  
pramlintide therapy, 169  
reference resources. *See* Reference resources.  
Type 1.5 diabetes, 23, 24t-25t, 29-31  
Type 1A diabetes, 23, 24t-25t  
Type 1B diabetes (idiopathic diabetes), 23, 24t-25t, 27  
Type 2 diabetes, 23, 24t-25t, 28-29  
    pramlintide therapy for, 189  
    vs type 1 diabetes, 47-48  
Type 3 diabetes (double diabetes), 24t-25t, 31-32  
  
UKPDS (United Kingdom Prospective Diabetes) study,  
    141-142, 220, 231  
Ultralente, 71, 72t, 77, 79-80, 90, 94, 120  
Ultram, 234  
Unexplained hyperglycemia, 127-128  
Unexplained ketoacidosis, 127-128  
United Kingdom Prospective Diabetes study. *See* UKPDS  
    (United Kingdom Prospective Diabetes) study.  
US Food and Drug Administration. *See* FDA (Food and  
    Drug Administration).

Vardenafil, 241  
Viagra, 241  
Viral infections, 40  
  
Zelnorm, 238